Vaxart Inc (NASDAQ: VXRT)’s stock price has decreased by -25.06% compared to its previous closing price of $0.43. However, the company has seen a -35.29% decrease in its stock price over the last five trading sessions. globenewswire.com reported 2025-06-13 that SOUTH SAN FRANCISCO, Calif., June 13, 2025 (GLOBE NEWSWIRE) — Vaxart, Inc. (Nasdaq: VXRT) (“Vaxart” or the “Company”), a clinical-stage biotechnology company developing a range of oral recombinant pill vaccines based on its proprietary delivery platform, today held its Annual Meeting of Stockholders (the “Annual Meeting”) in a virtual-only format. Preliminary results from the Annual Meeting indicate that two proposals were approved and two proposals were rejected by Vaxart stockholders.
Is It Worth Investing in Vaxart Inc (NASDAQ: VXRT) Right Now?
Additionally, the 36-month beta value for VXRT is 1.14. There are mixed opinions on the stock, with 3 analysts rating it as a “buy”, 0 rating it as “overweight”, 0 rating it as “hold”, and 0 rating it as “sell”.
The public float for VXRT is 222.15M and currently, short sellers hold a 9.53% ratio of that float. The average trading volume of VXRT on July 08, 2025 was 4.30M shares.
VXRT’s Market Performance
VXRT stock saw a decrease of -35.29% in the past week, with a monthly decline of -20.79% and a quarterly a decrease of -15.61%. The volatility ratio for the week is 16.99%, and the volatility levels for the last 30 days are 15.03% for Vaxart Inc (VXRT). The simple moving average for the last 20 days is -37.07% for VXRT stock, with a simple moving average of -46.70% for the last 200 days.
Analysts’ Opinion of VXRT
Many brokerage firms have already submitted their reports for VXRT stocks, with Oppenheimer repeating the rating for VXRT by listing it as a “Outperform”. The predicted price for VXRT in the upcoming period, according to Oppenheimer is $4 based on the research report published on August 15, 2024 of the previous year 2024.
Jefferies, on the other hand, stated in their research note that they expect to see VXRT reach a price target of $12, previously predicting the price at $13. The rating they have provided for VXRT stocks is “Buy” according to the report published on December 29th, 2021.
B. Riley Securities gave a rating of “Neutral” to VXRT, setting the target price at $9 in the report published on June 29th of the previous year.
VXRT Trading at -30.91% from the 50-Day Moving Average
After a stumble in the market that brought VXRT to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -70.09% of loss for the given period.
Volatility was left at 15.03%, however, over the last 30 days, the volatility rate increased by 16.99%, as shares sank -19.09% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -6.90% lower at present.
During the last 5 trading sessions, VXRT fell by -35.29%, which changed the moving average for the period of 200-days by -65.95% in comparison to the 20-day moving average, which settled at $0.5085. In addition, Vaxart Inc saw -52.77% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Lo Steven, the President, Chief Exec Officer of Vaxart Inc, purchase 100,000 shares at $0.49 during a trade that took place back on May 19 ’25, which means that Lo Steven is holding 100,000 shares at $49,000 based on the most recent closing price.
Stock Fundamentals for VXRT
Current profitability levels for the company are sitting at:
- -0.89% for the present operating margin
- 0.17% for the gross margin
The net margin for Vaxart Inc stands at -1.23%. The total capital return value is set at -0.7%. Equity return is now at value -114.74%, with -47.02% for asset returns.
Based on Vaxart Inc (VXRT), the company’s capital structure generated 0.27 points at debt to capital in total, while cash flow to debt ratio is standing at -1.97. The debt to equity ratio resting at 0.37. The interest coverage ratio of the stock is -36.15.
Currently, EBITDA for the company is -54.87 million with net debt to EBITDA at 0.34. When we switch over and look at the enterprise to sales, we see a ratio of 1.29. The receivables turnover for the company is 2.94for trailing twelve months and the total asset turnover is 0.3. The liquidity ratio also appears to be rather interesting for investors as it stands at 0.64.
Conclusion
In conclusion, Vaxart Inc (VXRT) has seen bad performance in recent times. Analysts have a bullish opinion on the stock, with some rating it as a “buy” and others rating it as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
